A small cheque with a big signal

Recently in August 2026, 4DMedical tipped A$3.4 million into a little-known American software firm, RevealDx, and signed a deal to distribute its lung-nodule tool. On its own, the cheque is minor. But it capped a remarkable ten-week run in which the Melbourne-based imaging company (ASX: 4DX) has bought a European rival, locked in access to more than 170 US clinics, drawn the attention of the US Congress and won marquee hospital contracts. The market has warmed to the story. Yet the same stretch exposed the tension at the heart of the Investment case: 4DMedical (ASX:4DX) is assembling an ambitious cardiopulmonary imaging ecosystem while still burning roughly $10 million a quarter. The question for investors is whether reimbursed, Recurring Revenue arrives before the deal-making outpaces the balance sheet.

 

A ten-week deal blitz

Over a ten-week stretch between late spring and early August, 4DMedical fired off announcement after announcement. Earlier in the run it signed a three-year commercial agreement with SimonMed Imaging, one of the largest US outpatient radiology networks, to deploy its CT:VQ and LDAf software across more than 170 sites in 10 states. Days later, it agreed to acquire Vienna-based contextflow — its first European foothold — for about $18.56 million cash upfront plus shares and performance options, a deal that also carried roughly €19 million ($30.8 million) in accumulated tax losses. Shortly after, it unveiled a US$2 million CLEAR clinical program with Mass General Brigham targeting pulmonary embolism.

Then came Washington. Recently in July 2026, a bipartisan bill — the AIR CARE for Vets Act (H.R. 9666) — was introduced in the US House, directing the Department of Veterans Affairs to run a pilot using 4D functional lung imaging. The RevealDx investment recently in August 2026 then folded an FDA-cleared lung-nodule tool into the group.

 

Why it matters

For years 4DMedical’s bottleneck has been distribution, not technology. Its XV Technology and CT:VQ products turn ordinary CT scans into functional maps of how air and blood move through the lungs — clever science that struggled to reach patients through a hospital-by-hospital sales grind. The SimonMed deal, priced per scan, hands the company a ready-made outpatient channel. contextflow and RevealDx add complementary AI tools and a European base, letting 4DMedical pitch a bundle rather than a single test. The strategy has shifted from selling one clever product to owning a slice of the cardiopulmonary imaging workflow.

 

The numbers that matter

The March-quarter Appendix 4C, the last full update before this feature, showed why patience is required. Operating Revenue for the nine months to 31 March 2026 was $5.0 million, up 12% year-on-year, with underlying software revenue up 24% and gross margins above 90%. Scan volumes are climbing fast: 86,200 in the March quarter alone, a 79% jump, taking the year-to-date tally near 240,000 across 477 active sites. Customer cash receipts, though, were just $1.4 million for the quarter. Net operating cash outflow was $10.2 million, down about 10% on the prior period but still substantial. Offsetting that, two placements earlier in the year — $150 million at $3.80 and $83 million at $5.90 — left the company with $203 million cash at 31 March, or $282.7 million pro forma. New contracts with the University of Chicago Medicine, Mayo Clinic and GSK lengthen the reference list.

 

A large, under-served market — if reimbursement follows

4DMedical is chasing a genuinely big opportunity. Respiratory disease is widespread and poorly served by decades-old tools such as spirometry, which gauges overall lung function but cannot show where a problem sits. Functional imaging promises regional detail without extra radiation or contrast dye. The company pegs its addressable market at more than US$4.5 billion across three continents, and frames pulmonary embolism alone — roughly 5 million CT pulmonary angiograms a year in the US — as a US$2.5 billion prize. The swing Factor is reimbursement. RevealDx’s nodule tool already qualifies for US Medicare payment under Category III CPT codes 0721T and 0722T; CT:VQ’s own reimbursement pathway is less mature, which is why SimonMed’s pledge to help build payer evidence matters as much as the site count.

 

The bull case

Bulls point to momentum on nearly every front: scan volumes almost doubling, software revenue compounding at 24%, a $200 million-plus war chest, inclusion in the S&P/ASX 200 from April, and a first-mover FDA clearance for CT-based VQ imaging granted in September 2025. If even a slice of the SimonMed network ramps to routine use, per-scan Economics at 90%-plus margins could scale quickly. The Veterans bill, if enacted, would add federal validation and a recurring customer.

 

The risks

The bear case is equally clear-eyed. At about $10 million a quarter, the cash burn is real, and the company has repeatedly returned to the market — the recent raises diluted holders, and further issuance is possible if commercial revenue lags. Reimbursement for CT:VQ is unsettled, and US radiology adoption can be slow. The Veterans opportunity is easily overstated: the bill authorises up to roughly US$20 million for a pilot (one report frames it as US$5 million a year over five years), it sits at committee stage, names no supplier, and no contract has been awarded. Acquisitions such as contextflow also carry integration risk.

 

What happens next

Several catalysts loom. First, the FY26 full-year result, due in coming weeks, will show whether the second half accelerated. Second, completion and integration of contextflow, expected from late July. Third, early scan-volume data from the SimonMed rollout — the first real test of the outpatient model. Fourth, the passage of H.R. 9666 through Congress. Fifth, any concrete movement on US reimbursement codes for CT:VQ, the single biggest lever on long-term revenue.

 

Conclusion

4DMedical has spent 2026 converting a strong Balance Sheet into strategic reach, stitching together US distribution, European operations and a widening suite of AI imaging tools. The logic is coherent: own more of the cardiopulmonary workflow, then let rising scan volumes do the compounding. The execution risk sits in the gap between the two numbers that define the company right now — $5 million of nine-month revenue against $10 million of quarterly cash burn. That gap is why the deal-making, however energetic, still needs to become recurring, reimbursed revenue. For investors, the next few quarters of scan data and the FY26 accounts will matter far more than any single headline. This is general information, not financial advice.